Vivani Medical, Inc. (NASDAQ: VANI) shares dropped in price Wednesday, as the Alameda, Calif.-based clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced promising preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight individuals.
These results reinforce the company’s commitment to addressing chronic weight management and other chronic diseases by leveraging its proprietary NanoPortal™ implant technology which is designed to enable smooth and steady delivery of therapeutic molecules including GLP-1 therapy. This development marks a significant advancement in improving medication adherence and patient convenience, addressing a critical gap in the treatment of chronic diseases including obesity and type 2 diabetes.
Said CEO Adam Mendelsohn, “Products containing semaglutide generated $25 billion in 2024 and demand for these products continues to soar. Since over half of these patients regularly miss doses as indicated by real-world medication adherence data, we believe that there is a tremendous opportunity for a more convenient delivery option that will eliminate missed doses and thereby improve real-world health outcomes.
“We continue to believe that the primary expected advantages of our proprietary NanoPortal implant technology, improving medication adherence and medication tolerability, have the potential to transform and expand the adoption of GLP-1 therapy in the future.”
VANI dipped 3.5 cents, or 3.2%, to $1.06.
